June 08, 2026

What the Biggest ASCO Cancer Research Updates Could Mean for Patients

Each year, the American Society of Clinical Oncology Annual Meeting brings together cancer specialists from around the world to share the research most likely to shape the next chapter of cancer care. This year’s major updates point to several important themes: more precise treatment, smarter use of surgery and chemotherapy, new approaches for difficult-to-treat cancers and a growing recognition that supportive care, including exercise, can be part of cancer treatment planning.

Baptist Health South Florida

May 13, 2026

Global Review Shows Impact of Exposure to Air Pollution on Cancer Risk and Mortality

A new report released by the Union for International Cancer Control shows that people exposed over the long term to fine particulate matter (PM2.5) (such as vehicle exhaust, wildfires, wood burning) h...

The ASCO Post

May 12, 2026

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

The ASCO Post

May 12, 2026

Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants

Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American...

The ASCO Post

May 12, 2026

Unique Phase I NSCLC Trial Sites Decreasing in United States

The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant conso...

The ASCO Post

May 07, 2026

Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies 

Eugene M. & Christine E. Lynn Cancer Institute has treated its first patient with tarlatamab, marking an important milestone in the expansion of advanced cancer therapies available to patients in Palm Beach County and the surrounding region.

Baptist Health South Florida

May 04, 2026

Zoldonrasib in Patients With KRAS G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...

The ASCO Post

April 29, 2026

Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC

As reported in the Journal of Clinical Oncology by Li et al, long-term follow-up of a Chinese phase II trial (TRUST-I) showed prolonged activity with taletrectinib in patients with ROS1 mutation–posit...

The ASCO Post

April 29, 2026

Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC

As reported in the Journal of Clinical Oncology by Li et al, long-term follow-up of a Chinese phase II trial (TRUST-I) showed prolonged activity with taletrectinib in patients with ROS1 mutation–posit...

The ASCO Post

April 29, 2026

Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC

As reported in the Journal of Clinical Oncology by Li et al, long-term follow-up of a Chinese phase II trial (TRUST-I) showed prolonged activity with taletrectinib in patients with ROS1 mutation–posit...

The ASCO Post